The following table sets forth the gross carrying amount, accumulated amortization and net carrying amount of our intangible assets as of June 30, 2020 and December 31, 2019: (Details) - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2020	Dec. 31, 2019
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Accumulated Amortization	$ (609,982)	$ (478,983)
Intangible Assets, Gross (Excluding Goodwill)	6,552,855	5,737,194
Intangible assets, net	5,942,873	5,258,211
Multiple Trademarks [Member]
Finite-Lived Intangible Assets [Line Items]
Indefinite-Lived Trademarks	338,681	294,813
Indefinite-lived Intangible Assets (Excluding Goodwill)	338,681	294,813
Approved Hormone Therapy Drug Candidate Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	3,997,263	3,463,082
Finite-Lived Intangible Assets, Accumulated Amortization	(609,982)	(478,983)
Finite-Lived Intangible Assets, Net	$ 3,387,281	$ 2,984,099
Finite-Lived Intangible Assets, Remaining Amortization Period	12 years 6 months	13 years
Hormone Therapy Drug Candidate Patents - (Pending) [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	$ 2,216,911	$ 1,979,299
Finite-Lived Intangible Assets, Net	$ 2,216,911	$ 1,979,299